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Abstract
Background: COPD-6™ is a lung function testing device for a rapid pre-spirometry testing to screen-out at-risk
individuals not having COPD and indicating those at risk. The aim of this study was to validate COPD-6™ lung function
testing (index test) in general practice in discriminating patients with COPD out of the population at risk - smokers/ex-
smokers with no previous diagnosis of COPD, using measurements at tertiary care as reference standard.
Methods: Consecutive 227 subjects (115 women, 185 smokers/42 ex-smokers, ≥20 pack-years) with no previous
diagnosis of COPD, aged 52.5 (SD 6.8) years from 26 general practitioners (GPs) were recruited, lung function tested
with COPD-6™, referred to the tertiary institution for repeated COPD-6™ testing followed by spirometry with a
bronchodilator (salbutamol), examination, and pulmonologist consultation for the diagnosis and severity of COPD.
Results: COPD was diagnosed in 43 subjects (18.9 %), with an AUC of 0.827 (95 % CI 0.769-0.875, P < 0.001) for the
diagnosis of COPD when lung function was measured using COPD-6™ in GP’s office with a specificity of 100 % (95 % CI,
97.95–100 %) but a very low sensitivity of 32.56 % (95 % CI, 20.49–47.48 %). Significant agreement for forced expiratory
volume in 1 s measured at GP’s office and at lung function lab was found (mean difference 0.01 L, p = 0.667) but not for
other measured parameters (p < 0.001 for all).
Conclusions: Our study results point out that active case finding in a population at risk for COPD should be instituted
(almost 20 % of undiagnosed COPD). Based on our results lung function testing with COPD-6™ can substitute spirometry
testing in cases where it is not readily available to the patient/physician taken into account that the traditional FEV1/FEV6
cutoff value of <0.7 is not the only criterion for diagnosis and/or further referral.
Trial registration: ClinicalTrials.gov Identifier NCT01550679 Registered 28 September 2014, retrospectively registered
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QoL, Quality of life; ROC, Receiver operator curve; SD, Standard deviation
Background
COPD is one of the leading causes of morbidity and
mortality worldwide [1]. Existing prevalence data show
variations due to survey methods reflecting also a wide-
spread under-diagnosis of COPD, even in patients with
developed respiratory symptoms [2–5]. On the other
hand patients with a mild COPD already have substan-
tial reduction in all parameters of health related QoL
(HRQoL) [6]. Modern strategies for COPD management
are stressing the importance of primary care physician’s
office-based assessments of patients at risk, thus signifi-
cantly increasing the number of timely diagnosed COPD
patients [7].
Spirometry with the documented post-bronchodilator
FEV1/FVC <0.70 is required to make a diagnosis of
COPD in a clinical context of the disease [1]. Spirometry
in general practitioners’ (GPs) office would be adequate
to make a diagnosis, but there are many obstacles to that
strategy; the price of equipment, reimbursement strat-
egies, quality of spirometry in such an environment, in-
sufficient training, and experience in testing [8].
Unavailability of a spirometry often leads to over-
diagnosis of COPD, made only based on symptoms and
exposure data without confirmatory lung function test-
ing, leading to overtreatment and negative impact on
morbidity and mortality [9–11].
COPD-6™ (4000 COPD-6™ Respiratory Monitor, Vita-
lograph Ltd., Buckingham, UK) is a cheap, simple lung
function testing device approved as a rapid pre-
spirometry testing tool to screen-out the at-risk individ-
uals who do not have COPD and indicate those that
may be at risk. It is a simple device, easy to learn how to
operate, having the readout without the risk of false
COPD negatives, thus focusing spirometry resources on
a smaller population with most of the risk. Four major
problems could arise from using COPD-6™ as a screen-
ing device instead of spirometry: (1) using FEV6 instead
of FVC could underestimate the later; (2) no post-
bronchodilator testing; (3) no flow-volume curve presen-
tation; (4) a single criterion for fixed airflow limitation
as defined in GOLD initiative (FEV1/FEV6 < 0.70) thus
possibly producing a significant over-diagnosis in elderly
(>70 years of age) according to The Global Lung Func-
tion Initiative data [12].
Having all that in mind, we wanted to explore the
diagnostic accuracy of COPD-6™ in a population of
smokers/ex-smokers with a significant exposure to
cigarette smoke, with no previous diagnosis of COPD, in
a general practice setting comparing it to the ‘gold
standard’, spirometry conducted in a lung function la-
boratory at the tertiary care level (university and teach-
ing hospitals) by experienced staff with special training.
This is a population with expected 25 % of undiagnosed
COPD cases in which such case identification is recom-
mended [1]. So, the aim of this study was to validate
COPD-6™ lung function testing (index test) in general
practice in discriminating patients with COPD out of
the population at risk - smokers/ex-smokers with no
previous diagnosis of COPD, using measurements at ter-
tiary care as reference standard. The secondary goal was
to assess the agreement between lung function measure-
ments between methods (COPD-6™ vs. spirometry) and
between health care settings (primary vs. tertiary care).
Methods
Study framework
This prospective cohort study was a part of broader re-
search project (Early detection of COPD patients in
GOLD 0 (smokers) population – MARKO project). The
whole protocol of the MARKO project can be found at
https://clinicaltrials.gov/ct2/show/NCT01550679. The
study was approved by the local ethics committee and
conducted according to the Declaration of Helsinki and
other relevant international and national laws. The pa-
tients were approached by their GPs during any (unre-
lated to respiratory problems) visit to their office if they
were smokers or ex-smokers of the predefined age group
for the study together with the prescreening for inclu-
sion/exclusion criteria using a structured interview. Eli-
gible patients were given the Informed consent
document with enough time to read it and to discuss
any relevant issues regarding the study before they
signed the written consent. They were informed about
the prospective nature of the study and their right to
withdraw their consent and claim the withdrawal of all
gathered data and destroying all biological samples at
any time without any explanation, obligation or conse-
quence from their side. All participants signed the writ-
ten consent before starting any procedure for the study.
Subjects
The consecutive patients from 26 GPs (representing the
same number of GP offices) were recruited based on in-
clusion/exclusion criteria. We decided on consecutive
patients based on the limited number of insured persons
under the care by each GP (approx. 1700), and relatively
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low response rate for a public health campaigns in our
country. Inclusion criteria were: written consent;
smokers/ex-smokers of either sex, aged 40–65 years with
a smoking history of at least 20 pack-years (calculated as
number of cigarettes smoked per day multiplied by the
number of years of smoking divided by 20); with no pre-
vious diagnosis of COPD. Exclusion criteria were: any
clinically relevant chronic disease significantly affecting
QoL at the time of the first visit (cardiovascular, cerebro-
vascular, diabetes, hepatitis, nephropathy, chronic dialy-
sis, systemic disorder, cancer); immunosuppressive
therapy; preceding acute respiratory disease 4 weeks be-
fore the visit; hospitalization for any reason during past
3 months; myocardial infarction, cerebrovascular infarc-
tion or transient ischemic attack during past 6 months;
diagnosis of asthma; and an inability to perform the
diagnostic protocol. Exclusion criteria were introduced
not to exclude patients having comorbidities common in
COPD, but to exclude the ones that represent acute/sub-
acute clinical states/disorders or states of recovery from
major clinical disorders representing an absolute or rela-
tive contraindication for spirometry or significantly in-
fluencing the diagnostic process or an already present
diagnosis of respiratory disorder (e.g., asthma).
Study workup
All GPs went through short small groups training and
were provided with the COPD-6™ devices. GPs were not
extensively trained in spirometry or assessed for their
skill level because we wanted that the measurements
would be performed as close as possible to the regular
real-life clinical situation where GPs scarcely use these
measurements. After the examination at the GP’s office
and lung function testing with COPD-6™ (index test),
patients were referred after 2–4 weeks to one of the ter-
tiary institutions to a designated team consisting of a
pulmonologist, research nurse and lung function labora-
tory technician. Standard diagnostic workup consisted of
repeated COPD-6™ lung function testing followed by
spirometry with a bronchodilator (salbutamol), history,
physical examination and specialist consultation. Pa-
tients with no previous diagnosis of COPD were chosen
to avoid bias coming from a previous knowledge of a
diagnosis but allowing a significant subsample of subject
with COPD (according to previous studies up to 25 % of
subjects in this population has an undiagnosed COPD)
[1]. To avoid the second possible bias, the team at the
tertiary care institution was blinded for the results of the
COPD-6™ measurements performed at GP’s office. After
the workup conducted at the tertiary care institution the
pulmonologist made the diagnosis and severity assess-
ment of COPD according to GOLD: relevant exposure,
respiratory symptoms characteristic for COPD and fixed
airflow limitation (post bronchodilator FEV1/FVC <0.70)
[1]. This was used as a reference standard for this study.
Lung function measurements
Lung function measurements using COPD-6™ were per-
formed according to the manufacturer’s recommenda-
tions and ATS/ERS guidelines [11]. Measurements were
repeated until 3 technically satisfactory efforts were per-
formed. COPD-6™ has a quality assessment built in the
device and marks the technically inadequate measure-
ment with the exclamation mark. Exclamation mark ap-
pears when the time of expiration is too short or
coughing during expiration was present. After 3 technic-
ally satisfactory efforts the device automatically choses
the best one and these results were recorded as absolute
values for forced expiratory volume in 1 s (FEV1 in L),
forced expiratory volume in 6 s (FEV6 in L), FEV1/FEV6
ratio (%), and lung age (years) and as % of predicted
values for FEV1, FEV6 and FEV1/FEV6 according to pre-
diction equations already in the device calculated ac-
cording to sex, age and height. The device uses the pre-
specified cut-off levels for visually suggesting the prelim-
inary diagnosis of COPD (FEV1/FEV6 ratio of <0.7) and
assesses the severity according to GOLD initiative [1], so
we used this criterion as a positive index test for further
comparisons. The same procedure was followed at both
sites (GP’s offices and lung function labs in a tertiary
care hospitals).
Spirometry was performed using computerized pneu-
motachographs (Jaeger®, CareFusion, CA, USA) using
the same procedure at all clinical sites (lung function
labs at tertiary hospitals) according to ATS/ERS guide-
lines [13]. The best of three technically satisfactory ef-
forts was recorded. Bronchodilator test was performed
by repeated spirometry 20 min after the inhalation of
400 mcg of salbutamol using the inhalation chamber.
Absolute values of FEV1, forced expiratory capacity
(FVC), FEV1/FVC ratio were together with sex, age and
height entered into the Excel sheet (Microsoft® Excel®
2013, Microsoft Corporation, USA) for all subjects and
using predicted values equation from Quanjer, % of pre-
dicted was calculated in a single act using Excel [14].
Tertiary care postbronchodilator spirometry measure-
ments at lung function laboratory were used as reference
standard for this study.
Data analyses
Data analysis was performed using STATISTICA ver-
sion 12 (StatSoft, Inc., OK, USA) and MedCalc Statis-
tical Software version 15.8 (MedCalc Software bvba,
Ostend, Belgium; https://www.medcalc.org; 2015).
Minimal sample size of 70 subjects (14 positive and
56 negative) was calculated for the expected area
under the curve (AUC) of 0.8 with a statistical power
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of 95 % (beta 0.05) and alpha of 0.05. Categorical
data was presented as absolute and relative (%) num-
bers. Continuous variables were presented as mean
and standard deviations (SD). Categorical data was
compared between subgroups using chi-square (χ2)
test and continuous variables using Student’s t-test or
Mann-Whitney U test and analysis of variance
(ANOVA). The criteria to use Student’s t-test and
ANOVA were checked and fulfilled before the tests
were performed. Agreement between lung function
measurement methods was conducted using Bland-
Altman statistics and plots. Utility of FEV1/FEV6 mea-
sured using COPD-6™ at GP’s office (index test) for
diagnosing COPD was analyzed comparing it to the
reference standard using receiver operator curve
(ROC) analysis and data was presented as AUC to-
gether with sensitivity, specificity and positive and
negative predictive values together with 95 % confi-
dence intervals (CIs). P < 0.05 was used as statistically
significant for all analyses.
Results
Out of 326 consecutive prescreened smokers of eligible
age and smoking history, 227 (69.6 %) subjects (115
women) at risk for COPD (185 smokers and 42 ex-
smokers) aged 52.5 (SD 6.8) years were included in this
study (78 refused to participate and 21 were excluded
based on exclusion criteria, Fig. 1). The basic demographic
data for included subjects are displayed in Table 1. The
diagnosis of COPD (reference diagnosis) was made in 43
(18.9 %) subjects with no significant difference between
men and women (χ2 = 2.711, P = 0.100) or between
smokers and ex-smokers (χ2 = 1.763, P = 0.185). Cross-
tabulation of an index test positivity against the reference
standard is presented in Table 2. No significant difference
was found between subjects with COPD and no-COPD
for age (t = 1.139, P = 0.256), presence of comorbid
disorders (55.5 %) and chronic treatment (χ2 = 0.049,
P = 0.825; χ2 = 0.125, P = 0.724; respectively), BMI
(t = 0.100, P = 0.921) or smoking habit (p > 0.100 for
all parameters of smoking habit). Also no clustering
Fig. 1 Diagram of flow of patients through the study
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of COPD diagnosis, demographics or smoking habit
data was evident for different GPs (p > 0.100 for all
comparisons). In Table 3 lung function data is pre-
sented according to the existence and severity of
COPD (24, 10.4 % GOLD stage 1 and 19, 8.2 %
GOLD stage 2).
ROC curve analyses of FEV1/FEV6 measurements for
the diagnosis of COPD using COPD-6™ at the GPs office
and at the lung function lab at the tertiary care hospital
gave an AUC of 0.827 (95 % CI 0.769–0.875, P < 0.001;
Fig. 2) and 0.849 (95 % CI 0.788–0.898, P < 0.001) being
significantly different to spirometry (AUC 0.961, 95 % CI
0.920–0.984, z statistic = 2.501, P = 0.012; z statistic =
4.058, P < 0.001; respectively). Using the usual (pre-speci-
fied) threshold of <0.7 for FEV1/FEV6 for the diagnosis of
COPD for the lung function (COPD-6™) values measured
at GP’s offices gave the highest specificity of 100 % (95 %
CI, 97.95–100 %) but a very low sensitivity of 32.56 %
(95 % CI, 20.49–47.48 %) with a PPV of 100 % (95 % CI,
78.47–100 %) and NPV of 86.38 % (95 % CI, 81.13–
90.35 %).
Exploratory analyses using the change in threshold
gave somewhat better overall results with a change of
threshold to ≤0.78 for FEV1/FEV6 that gave a specificity
of 88.95 % (95 % CI, 83.83–92.60 %) with a sensitivity of
70.97 % (95 % CI, 54.72–85.03 %), a PPV of 52.38 %
(95 % CI, 37.72–66.64 %), NPV of 94.71 % (95 % CI,
89.90–97.76 %). The highest NPV (95.74 %, 95 % CI
90.93–98.79 %) was achieved with a cut-off value of 0.85
with the negative likelihood value of 0.26 (95 % CI,
0.20–0.33).
Methods comparison between lung function values
measured at GP’s offices and values measured at lung
function labs at tertiary care hospitals are shown in Table 4
and Fig. 3. FEV1 values measured using COPD-6™ at GP’s
offices showed small differences with the same measure-
ment at tertiary care and no clinically relevant differences
when compared with spirometric measurement and post-
bronchodilator one (mean difference, −0.12 L and
−0.16 L, P < 0.001 for both, Bland-Altman statistics;
Table 4 and Fig. 3). Point of care comparison for FEV6
(primary vs. tertiary care) showed clinically non-relevant
difference (Table 4 and Fig. 3) but method comparison
with spirometric and postbronchodilator measurements of
FVC showed significant and clinically relevant differences
(mean difference, −0.66 L and −0.60 L, P < 0.001 for both,
Bland-Altman statistics) when compared to reference
measures with a trend of increasing the difference with
larger values (Table 4 and Fig. 3). Comparison of FEV1/
FEV6 values measured using COPD-6™ showed significant
and clinically relevant differences (mean difference, 4.2 %,
10.2 % and 8.6 %, P < 0.001 for all, Bland-Altman statistics)
when compared to reference measures (FEV1/FEV6,
FEV1/FVC and postbronhodilator FEV1/FVC) at tertiary
care hospitals with a trend of increasing the difference
with lower values (Table 4 and Fig. 3) thus showing a sys-
tematic bias.
Discussion
This study has three main findings: (1) COPD-6™
showed moderate accuracy with high specificity but low
sensitivity for COPD; (2) COPD-6™ could be with certain
restrictions reliably used in GP’s offices; (3) in the popu-
lation at risk for COPD, there was a substantial number
(18.9 %) of undiagnosed patients. Our data comparing
COPD-6™ measurements with a reference standard (ter-
tiary care COPD diagnosis) shows that COPD-6™ can be
Table 1 Demographics, smoking habit, presence of comorbid disorders and chronic treatment other than that for COPD according
to final COPD diagnosis (N = 227)
Variables All (N = 227) COPD (n = 43) Non-COPD (n = 184) Statistics
Women (%) 115 (50.7) 17 (39.5) 99 (53.2) χ2 = 2.711, P = 0.100
Age (years), mean ± SD 52.5 ± 6.8 53.6 ± 7.0 52.3 ± 6.7 t = 1.139, P = 0.256
BMI (kgm−2), mean ± SD 26.5 ± 4.2 26.5 ± 5.2 26.5 ± 3.9 t = 0.100, P = 0.921
Active smokers (%) 185 (84.9) 32 (84.2) 153 (85.0) χ2 = 0.015, P = 0.902
Years of smoking, mean ± SD 30.6 ± 6.9 32.0 ± 6.4 30.3 ± 6.9 z = 1.641, P = 0.101
Cigarettes/day, mean ± SD 24.6 ± 9.1 24.4 ± 8.0 24.6 ± 9.2 z = 0.241, p = 0.809
Pack-years, mean ± SD 37.9 ± 17.4 39.1 ± 14.3 37.5 ± 17.5 z = 1.310, p = 0.190
Presence of comorbid disorders (%) 126 (55.5) 22 (51.2) 104 (56.5) χ2 = 0.049, P = 0.825
Chronic treatment (%) 99 (43.6) 16 (37.2) 83 (45.1) χ2 = 0.125, P = 0.724
χ2 chi-square test results, t result of Student’s t-test, z result of Mann-Whitney U test, SD standard deviation, BMI body mass index calculated as the ratio of body
weight in kg and squared body height in meters
Table 2 Cross-tabulation of the results of index test (COPD-6™)













Total 43 184 227
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used with enough accuracy in screening for COPD on a
primary care level. Exploratory analyses with the change
in threshold showed the possible improvement in the ac-
curacy, but this data needs additional confirmatory stud-
ies to be conducted using these values as a pre-specified
ones. Although it is our opinion that based on substan-
tial number of undiagnosed patients screening for
COPD in a population at risk is valuable, this opinion
needs further corroboration based on the studies arguing
benefits coming from this effort.
Spirometry is the basis for diagnosing COPD but pri-
mary care providers, who first meet patients with re-
spiratory symptoms, do not always have access [15],
time or adequate training to use it [16]. In contrast to
spirometry, our study showed that COPD-6™ can be reli-
ably used in GP’s offices with the results that are
Table 3 Lung function (COPD-6™, spirometry) according to the presence and severity of COPD according to GOLD stages





(N = 227) (n = 184) (n = 24) (n = 19)
COPD-6™ FEV1 (% predicted) 94.3 ± 15.6 97.6 ± 13.3 90.9 ± 13.0 67.5 ± 12.2 F = 46.27 P < 0.001
FEV6 (% predicted) 93.9 ± 16.2 96.0 ± 15.3 94.7 ± 14.9 74.5 ± 13.7 F = 17.27 P < 0.001
FEV1/FEV6 (%) 0.845 ± 0.085 0.864 ± 0.071 0.781 ± 0.083 0.757 ± 0.117 F = 25.84 P < 0.001
Lung age (yrs) 60.7 ± 13.9 57.7 ± 11.1 64.0 ± 11.1 84.6 ± 15.7 F = 48.07 P < 0.001
Spirometry FEV1 (% predicted) 97.9 ± 15.3 101.5 ± 12.9 92.9 ± 10.2 71.1 ± 12.7 F = 51.50 P < 0.001
FVC (% predicted) 109.3 ± 17.0 110.8 ± 16.7 112.7 ± 11.8 91.1 ± 16.2 F = 13.29 P < 0.001
FEV1/FVC (%) 0.742 ± 0.073 0.761 ± 0.060 0.665 ± 0.055 0.650 ± 0.073 F = 49.14 P < 0.001
ΔFEV1 (%) 1.39 ± 4.00 1.40 ± 3.79 2.92 ± 4.25 −0.93 ± 7.68 F = 3.011 P = 0.051
Data for all variables is presented as mean ± standard deviation; FEV1 forced expiratory volume in 1 s, FEV6 forced expiratory volume in 6 s, FVC forced expiratory
volume, ΔFEV1 post-bronchodilator change in FEV1 (measured 20 min after inhalation of 400 μg of salbutamol), F – result of ANOVA for between
group comparisons
Fig. 2 ROC curve for the diagnosis of COPD using COPD-6™ at the GP’s office. ROC curve plot (AUC 0.827, 95 % CI 0.769–0.875, P < 0.001) was
based on FEV1/FEV6 measurements using COPD-6™ at the GP’s office using COPD diagnosis made by pulmonologist at tertiary care hospital as cri-
terion variable; dotted lines represent 95 % confidence intervals
Labor et al. BMC Family Practice  (2016) 17:112 Page 6 of 11
Table 4 Methods comparison (Bland-Altman statistics) for lung function measurements performed in a GP’s office and at lung
function lab (N = 227)
COPD-6™ at GP’s office
Lung function lab measurements FEV1 (L) FEV6 (L) FEV1/FEV6 (%)
COPD-6™ FEV1 (L) Δ (95 % CI) 0.01 (−0.05 to 0.03) NA NA
FEV6 (L) Δ (95 % CI) NA −0.17 (−0.24 to −0.12)* NA
FEV1/FEV6 (%) Δ (95 % CI) NA NA 4.83 (3.71 to 6.35)*
Spirometry FEV1 (L) Δ (95 % CI) −0.12 (−0.15 to −0.09)* NA NA
FVC (L) Δ (95 % CI) NA −0.66 (−0.72 to -0.59)* NA
FEV1/FVC (%) Δ (95 % CI) NA NA 10.24 (9.32 to 11.26)*
Post-bronchodilator spirometry FEV1 (L) Δ (95 % CI) −0.15 (−0.19 to −0.12)* NA NA
FVC (L) Δ (95 % CI) NA −0.60 (−0.65 to −0.54)* NA
FEV1/FVC (%) Δ (95 % CI) NA NA 8.52 (7.57 to 9.47)*
GP general practitioner, FEV1 forced expiratory volume in 1 s, FEV6 forced expiratory volume in 6 s, FVC forced expiratory volume, FVC forced expiratory volume, Δmean
difference of the index test (COPD-6™measurement at GP’s office) from the reference (tertiary care measurement), 95 % CI 95 % confidence interval NA not applicable
*P < 0.001
Fig. 3 Bland-Altman plots for between methods and points of care comparisons for lung function parameters. Bland-Altman plots are presented
as plots of difference between two measurements [y-axis] plotted against the mean of two measurements [x-axis]; graphs at columns represents
parameters measured using COPD-6™ at the GP’s office: first column – FEV1, second column – FEV6, third column – FEV1/FEV6; rows represent
mean of two measurements: first row – COPD-6™ at tertiary care, second row – spirometry (S), third row – postbronhodilator (PB) spirometry
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comparable to the measurements performed using the
same device by the highly experienced and trained
personnel.
Other studies evaluating the use of COPD-6™ differ in
many aspects from our study. The population at risk
was not strictly defined [7], the patients of older age
were included thus increasing the probability of false
positive results and inconclusive effects of screening
with spirometry [12, 17, 18], and the results of FEV1/
FEV6 measurements were not compared between GP’s
offices and lung function laboratory [19]. The results
were mainly used as an advanced case finding technique
and were not tested for diagnostic purposes. Different
cut-off values for FEV1/FEV6 ratios were suggested with
different sensitivity and specificity that didn’t meet the
criteria to establish the diagnosis of COPD [20, 21].
Based on the results of our study, the FEV1/FEV6 ratio
<0.7 measured at GP’s office has a specificity of 100 %
with positive predictive value of 100 % indicating that a
patient had a COPD and can be diagnosed in accordance
to other diagnostic criteria with no further lung function
testing needed. These results were good but significantly
worse than spirometry. The same was the case for the
FEV1/FEV6 ratio measured by COPD-6™ at a lung func-
tion lab at tertiary care hospitals using highly experi-
enced staff. The reason behind it, lies in the lack of real-
time visual control, present during spirometry, thus
underestimating the real value of FEV6 (a surrogate
measure for FVC). This produced a systematic bias over-
estimating the real value of FEV1/FEV6 ratio. This points
out that additional training should be provided to heath
care personnel at GP’s office to understand and
recognize this possible measurement bias.
Otherwise, our exploratory analysis showed that FEV1/
FEV6 ratio >0.85 measured at GP’s office had a NPV of
95.74 % and was reasonable to conclude that a patient
was not suffering from COPD and further testing was
indicated to reveal the reasons for respiratory symptoms.
A strategy of using this two cut-off values (FEV1/FEV6 <
0.7 to diagnose and >0.85 to rule-out COPD) could in-
crease the number of patients diagnosed at GP’s offices
and treated according to the current guidelines. A con-
firmatory study validating these thresholds should be
done using these cut-off values as a pre-specified goals.
If this thresholds are confirmed, only patients with the
FEV1/FEV6 ratio between the 0.7 and 0.85 should be re-
ferred for further lung function testing and (sub)special-
ist evaluation. Our results were based on the study
population from 40 to 65 years of age so in older popu-
lations recommendations from Global Lung Initiative
(GLI) to use lower limit of normal (LLN) for FEV1/FVC
(different from a fixed criterion of <0.7) should be taken
into account to prevent over diagnosing COPD in older
population [12].
Diagnosing COPD is important because it was shown
that undiagnosed patients with COPD have increased
mortality [22], morbidity [5, 23] and decreased quality of
life [24]. The treatment of such patients is delayed and
the probability of quitting smoking is diminished [25].
For a decision to start the implementation of active case
finding it is important to know the number of undiag-
nosed patients in a specific population [26]. There is evi-
dence of different diagnostic accuracy of physician’s
established diagnosis for COPD in different countries
and age groups [27]. Up till now, we didn’t have a scien-
tific data for our population. In our study, the number
of undiagnosed COPD patients in a population at risk is
approaching 20 % with almost half of them in advanced
stages of the disease (8.4 %). These data are important
for health authorities for decision making [28]. Our find-
ing was on a lower end of the results from literature ran-
ging from 20 % to more than 50 % of undiagnosed
COPD patients in at risk population [29, 30]. This is
probably the result of an overall education campaign
started in our country as early as the year 2000 with the
presentation of the COPD monograph (COPD guidelines
developed by the Croatian Respiratory Society), and
followed in subsequent years by the broad education
campaign for both GPs and pulmonologists according to
GOLD.
Based on the results of our study we could recom-
mend the clinical algorithm (Fig. 4) for the triage of pa-
tient at risk for COPD (smokers/ex-smokers with >20
pack-years having chronic respiratory symptoms or co-
morbidities associated with COPD) using lung function
testing with COPD-6™ at GP’s office (for the age group
of >70 cut-off value for the FEV1/FEV6 should be revised
to LLN according to GLI recommendations [12]): (1)
FEV1/FEV6 < 0.7 – treatment should be started accord-
ing to the current guidelines in an uncomplicated pa-
tient or referred to specialist for further assessment if a
patient is severe or has significant comorbidities; (2)
FEV1/FEV6 ≥ 0.7 and ≤0.85 – refer to pulmonologist for
further consultation; (3) >0.85 should consider alterna-
tive diagnosis than COPD. Using such an algorithm in
regular GP practice will allow GPs to make an early
COPD diagnosis or a proper specialist referral thus pro-
ducing more appropriate use of resources, cost savings
and task shifting. These effects are based on much
broader accessibility and lower price of services of gen-
eral practice and limited resources on the secondary/ter-
tiary care level considering the number of smokers in
general population (up to 30 % of adults) and COPD pa-
tients (up to 10 % of adults). Substantial positive effects
can be expected based on this broad accessibility regard-
ing early diagnosis of COPD allowing early preventive
interventions (quitting smoking) [25]. Although it can be
supposed that an early intervention already in
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asymptomatic subjects with fixed airflow limitation
could be beneficial there are no studies that confirm
such a hypothesis and possible benefits but also no harm
could be expected based on studies of therapeutic inter-
ventions in mild/moderate COPD [31].
The strengths of our study are based on the significant
number of indicative COPD patients diagnosed through
the diagnostic process (n = 43, 18.9 %), allowing us to
properly evaluate the accuracy of the tested device. Also
GPs were not extensively trained for the use of the
tested device and were not aware to be part of the study
thus allowing us to make conclusions that can be gener-
alized to a regular real life clinical setup. Using a “gold
standard” to make a COPD diagnosis on the referent
level (tertiary care) as a reference standard and evalu-
ation of lung function measurements conducted by GPs
against spirometry conducted by experienced staff pro-
vides us with an objective evaluation of the tested device
and GPs performance. The possible weaknesses of our
study are based on recruitment process that may not
represent the actual general practice population thus
possibly diminishing generalizability of our results, al-
though our analysis showed that there was no clustering
present regarding the characteristics of patients re-
cruited by different GPs and the proportion of undiag-
nosed COPD patients was comparable to other studies.
Also the age range of our study participants (40–65
years of age) does not allow us to generalize our results
outside this age range thus leaving the most question-
able population regarding the diagnostic criteria out of
our focus (>70 years of age). A bias could be present be-
cause there was no formal panel diagnosis of COPD
done, but the diagnosis was done using the harmonized
criteria by experienced pulmonologists (all pulmonologist
making a diagnosis were acting as trainers for more than
10 years for GOLD initiative in Croatia). So for our data
Fig. 4 Proposed clinical algorithm for the triage of patient at risk for COPD (smokers/ex-smokers with >20 pack-years having chronic respiratory
symptoms or comorbidities associated with COPD) using lung function testing with COPD-6™ at GP’s office
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to become more generalizable our research needs to be
conducted in a broader population (age 35–80 years, >10
pack-years) using also two threshold values that were
found out in our exploratory analyses (FEV1/FEV6 < 0.7
and >0.85).
Conclusions
Almost one fifth (18.9 %) of undiagnosed patients with
COPD in a population at risk (smokers/ex-smokers) in
our study points to the fact that active case finding should
be instituted in such a population. Based on the results of
our study lung function testing with COPD-6™ can in a
significant part substitute spirometry in cases where it is
not readily available to the patient/physician. Results of
lung function testing with COPD-6™ performed at GP’s of-
fices and in lung function laboratory were comparable, so
there is a possibility to establish the diagnosis of COPD
and start adequate treatment in a GP’s office in a substan-
tial number of patients at risk. This could be based on two
cut-of values for FEV1/FEV6, with the ratio <0.7 establish-
ing and >0.85 excluding the diagnosis of COPD. Before
the implementation in practice, the diagnostic criteria
should be checked for a specific population. Such ap-
proach could lead to a better diagnostic yield of COPD in
everyday practice diminishing the number of under-
diagnosed and over-diagnosed patients.
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